Blood Pressure in Children with Minimal Change Nephrotic Syndrome during Oedema and after Steroid Therapy: The Influence of Familial Essential Hypertension

2009 ◽  
Vol 32 (4) ◽  
pp. 258-262 ◽  
Author(s):  
Laure Monthe Kontchou ◽  
Giulia Liccioli ◽  
Ivana Pela
1993 ◽  
Vol 32 (7) ◽  
pp. 543-546 ◽  
Author(s):  
Takayasu OHTAKE ◽  
Masato KIMURA ◽  
Shigeto YOSHII ◽  
Naoki IKEGAYA ◽  
Shigekazu TAKAYANAGI ◽  
...  

2015 ◽  
Vol 54 (17) ◽  
pp. 2101-2108 ◽  
Author(s):  
Lingfei Zhao ◽  
Jun Cheng ◽  
Jingyi Zhou ◽  
Congcong Wu ◽  
Jianghua Chen

2020 ◽  
Vol 10 (1) ◽  
pp. 1-8
Author(s):  
Isao Kondo ◽  
Yohei Arai ◽  
Akiyoshi Hamada ◽  
Kota Yamada ◽  
Shingo Shioji ◽  
...  

Adults with minimal-change nephrotic syndrome (MCNS) generally receive oral prednisolone (PSL) at an initial dosage of 1.0 mg/kg/day for a minimum of 4 weeks, with 80% of patients achieving clinical remission. However, relapses are frequent, necessitating repeated treatment with high-dose PSL. Long-term treatment with high-dose steroids increases the risk of steroid toxicities, such as diabetes mellitus, gastric complications, infections, osteoporosis, and steroid-induced psychiatric syndrome (SIPS), which may compromise the patient’s quality of life. Strategies are therefore needed to reduce the dosage and duration of steroid therapy for frequently relapsing MCNS (FRNS). Here, we suggest a new combination therapy of low-dose and short-term steroid with cyclosporine (CsA). We encountered an adult patient who developed recurrence of FRNS with depression arising from SIPS and was treated using low-dose, short-term PSL combined with CsA. He was successfully treated with PSL at an initial dosage of 0.3 mg/kg/day (20 mg/day) for just 2 weeks combined with CsA, allowing earlier induction of complete remission. We then promptly reduced the dose of PSL to below a physiological dosage (5 mg/day) over 3 weeks without relapse after episodes of SIPS and quickly resolved psychiatric symptoms. CsA in combination with PSL can reduce the initial dosage of PSL, shorten the time to remission, and easily maintain clinical remission. This protocol appears clinically useful and potentially applicable as a future treatment strategy for FRNS troubled by SIPS.


2016 ◽  
Vol 6 (3) ◽  
pp. 209-215 ◽  
Author(s):  
Daisaku Ando ◽  
Gen Yasuda

Background: Proteinuria and nighttime blood pressure (BP) elevation are notable risk markers of chronic kidney disease and correlate closely with each other. However, daily urinary protein excretion (UPE) always fluctuates. In patients with minimal change nephrotic syndrome (MCNS), serum albumin concentrations (SAC) decrease but fluctuate less than UPE. We evaluated whether SAC is a reliable marker for proteinuria, and compared the relations among circadian BP changes, SAC, and UPE. Methods: In patients with MCNS (12 men and 11 women, 43 ± 18 years), blood and spot urine samples were collected on three consecutive days before treatment, and 24-hour BP was also measured on the three days. Then, an intervention study was conducted in the patients to examine circadian BP changes induced by treatment. Sleeping/waking BP ratio was analyzed as an indicator of circadian BP rhythm. Results: In the three-day measurements before treatment, mean coefficient of variation, an index of dispersion of data, for SAC was 7.4 ± 7.4%, which was markedly lower (p < 0.01) than 35.7 ± 15.4% for UPE. SAC correlated inversely with sleeping/waking systolic and diastolic BP ratios on all three days, whereas UPE did not correlate significantly with sleeping/waking diastolic BP ratio on day 3. Sleeping/waking systolic and diastolic BP ratios were 96 ± 5 and 95 ± 6%, and were higher (p < 0.05) than in healthy subjects (89 ± 8 and 88 ± 10%). Treatment improved hyperproteinuria and hypoalbuminemia, and was accompanied by decreases (p < 0.05) in sleeping and waking systolic/diastolic BP ratio to 91 ± 8 and 89 ± 9%. Conclusion: These findings suggest that reduced SAC in patients with proteinuria is associated with disrupted circadian BP rhythm.


Nephron ◽  
1999 ◽  
Vol 81 (1) ◽  
pp. 84-88 ◽  
Author(s):  
Machiko Yabana ◽  
Minoru Kihara ◽  
Yoshiyuki Toya ◽  
Kouichi Tamura ◽  
Katsumi Matsumoto ◽  
...  

2011 ◽  
Vol 45 (2) ◽  
pp. 179-185
Author(s):  
Hideyo Oguchi ◽  
Marohito Murakami ◽  
Takashi Araki ◽  
Mariko Meguro ◽  
Akinori Hashiguchi ◽  
...  

2012 ◽  
Vol 28 (5) ◽  
pp. 1225-1232 ◽  
Author(s):  
T. Takei ◽  
M. Itabashi ◽  
T. Moriyama ◽  
C. Kojima ◽  
S. Shiohira ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document